Background: Chagas cardiomyopathy, caused by Trypanosoma cruzi infection, continues to be a neglected illness, and has a major impact on global health. The parasite undergoes several stages of morphological and biochemical changes during its life cycle, and utilizes an elaborated antioxidant network to overcome the oxidants barrier and establish infection in vector and mammalian hosts. Trypanothione synthetase (TryS) catalyzes the biosynthesis of glutathione-spermidine adduct trypanothione (T(SH) 2 ) that is the principal intracellular thiolredox metabolite in trypanosomatids. Conclusions: TryS is essential for proliferation and survival of T. cruzi under normal and oxidant stress conditions, and provides an advantage to the parasite to develop resistance against currently used anti-trypanosomal drugs. TryS indispensability has been chemically validated with inhibitors that may be useful for drug combination therapy against Chagas disease.
Introduction
Chagas cardiomyopathy, caused by a hemoflagellate protozoan Trypanosoma cruzi (T. cruzi or Tc), is a major health concern in Latin America and is an emerging infectious disease in the United States, Europe, Japan, and other countries [1] . The World Health Organization estimates that~6-7 million people are infected worldwide, and 10000 deaths per year are caused by this illness [2] . Indeed, the global health impact of T. cruzi infection and Chagas disease might be underestimated due to a lack of access to health system and inaccurate diagnosis in the endemic regions. The majority of individuals infected with T. cruzi control the acute parasitemia and remain clinically asymptomatic for the rest of their life. However, 30-40% of the infected individuals develop clinical symptoms that progress from cardiac hypertrophic remodeling (wall thickening) to dilated cardiomyopathy and ultimately result in cardiac arrest and death. Up to 10% of the patients may also develop digestive, neurological or mixed alterations.
lesser extent nifurtimox (NFX), are administered for the treatment of acute T. cruzi infection [3] . However, these drugs are well tolerated by children only, and even then exhibit varying efficacy against different parasite isolates belonging to discrete typing units (DTU) I-VI. Limitedto-no-efficacy of BZ and NFX is observed in chronically infected adult patients, and currently recommended dosages of BZ and NFX produce adverse reactions including abdominal pain, nausea, vomiting, rash, decreased appetite and headache in adults, resulting in discontinuation of treatment [4, 5] . Adjuvant therapies that can decrease the efficacious dosages of BZ and NFX against T. cruzi infection will improve the tolerance and completion of anti-protozoal treatment.
Trypanothione synthetase (TryS) is a trypanosomatid-specific enzyme that catalyzes the two-step synthesis of trypanothione (T(SH) 2 ; N 1 ,N 8 -bis(glutathionyl)spermidine), from two molecules of glutathione (GSH; L-γ-Glu-Cys-Gly) and a spermidine core along with ATP consumption [6] . The N-terminal domain of TryS possesses weak amidase activity and can hydrolyze T(SH) 2 . The T(SH) 2 , together with its associated enzyme trypanothione reductase (TR), can carry out many of the antioxidant and metabolic functions of the glutathione / glutathione reductase and thioredoxin / thioredoxin reductase systems in other organisms [7] . TryS is shown to be essential for the survival of T. brucei and Leishmania species [8, 9] . Nevertheless, the role of TryS in T. cruzi biology is not delineated.
In this study, we aimed to investigate the role of TryS in various life cycle stages of T. cruzi. For this, we developed genetically-modified TryS-overexpressing parasites (referred as TryS hi ) and repressed TryS activity with small molecule inhibitors [10] . We evaluated the growth and survival of epimastigote (insect, replicative) and trypomastigote (infective) forms of TryS hi and control parasites in the absence and presence of oxidative stress and TryS inhibitors. We also determined the effect of TryS overexpression and TryS inhibition on the efficacy of antiprotozoal drugs (NFX and BZ) against T. cruzi. We discuss the biological significance of TryS in T. cruzi development, and the pharmacological potential that selective inhibition of TryS offers in a single or combined therapeutic approach with drugs in clinical use.
Materials and methods

Parasites, plasmids and transfection
T. cruzi SylvioX10/4 strain (ATCC 50823) was maintained and propagated as epimastigote axenic culture in liver infusion-tryptose medium (LIT) supplemented with heat-inactivated, 10% fetal bovine serum (FBS) . To obtain metacyclic trypomastigotes, epimastigotes were pelleted by centrifugation, resuspended (5 ×10 8 cell/ml) in Triatomine Artificial Urine (TAU) medium (190 mM NaCl, 17 mM KCl, 2 mM CaCl 2 , 8 mM phosphate buffer, 2 mM MgCl 2 , pH 6.8) and incubated at 28°C for 3 h. Thereafter, parasites were transferred to TAU3AAG medium (TAU supplemented with 0.035% sodium bicarbonate, 10 mM L-proline, 50 mM sodium glutamate, 2 mM sodium L-aspartate and 10 mM glucose) and incubated at 28°C for 72-96 h [11] . The mouse myoblast cell line C2C12 was purchased from the American Type Culture Collection and maintained in complete RPMI 1640 medium. The metacyclic trypomastigotes were used to infect C2C12 cells, and culture derived trypomastigotes were maintained and propagated by continuous in vitro passage in C2C12 cells. For metacyclogenesis assay, epimastigotes in exponential growth were synchronized by incubating in culture media without FBS for 24 h and then changed to LIT supplemented with 10% triatomine gut homogenate [12] at 28°C. The number of metacyclic and epimastigote forms were recorded on alternative days for 10 days by light microscopy. The difference between parasites stages was established according to its form and movement. Results are expressed as percentage of differentiated parasites.
The pTREX plasmid is designed to allow integration of the gene of interest in the ribosomal locus of T. cruzi [13] . To construct pTREX.TryS, forward and reverse oligonucleotides were designed using the GenBank AF311782.1 sequence to amplify full-length T. [14] supplemented with 300 µg/ml G418. Colonies were recovered after 30 days.
To confirm genomic integration of pTREX-TryS, total DNA was isolated from clonal populations of wild type (WT), and pTREX-or pTREX.TryS-transfected epimastigotes (1 ×10 7 each), as above. Total DNA (100 ng) was subjected to standard PCR reaction with oligonucleotides complementary to the neomycin resistance gene. A second set of oligonucleotides (T7-F and RIB-R) was used to check integration of the recombinant plasmid at the ribosomal locus in T. cruzi [15] . All oligonucleotides used in this study are listed in Supplemental S1 Table.
TcTryS antisera
The TryS protein sequence was analyzed by Kolaskar & Tongaonkar algorithm available at the ExPASy platform of the Swiss Institute of Bioinformatics (Lausanne, Switzerland), and the N-terminal peptide sequence (LQSLAVPFGCVQGY) predicted to exhibit maximum antigenicity was selected. The TryS peptide was synthetized at GenScript (Piscataway, NJ, USA) and conjugated to bovine serum albumin (BSA) by glutaraldehyde method. Polyclonal sera against TryS was raised by inoculating a rabbit by intradermal injection with 400 µg of BSA-conjugated TryS peptide in Freund´s complete adjuvant followed by two booster doses of 200 µg of TryS peptide with incomplete adjuvant at 30 days and 50 days after the first immunization. The serum was collected 15 days after the last immunization. To absorb the resulting anti-TryS antibodies, serum (5 ml) was incubated (1 h at room temperature followed by 12 h at 4°C) with 800 µg of recombinant TryS peptide coated onto nitrocellulose membrane. The antigen-bound antibody was eluted in 0.1 M glycine-HCl buffer (pH 2.7), and neutralized with 1/10th volume of 2 M Tris-HCl, pH 8.0.
Western blotting
T. cruzi epimastigotes and trypomastigotes (3 ×10 7 parasites) were frozen overnight and homogenized in 100 µl lysis buffer (50 mM HEPES, 200 mM NaCl , and 1% NP-40, pH 7.4) containing a protease inhibitor cocktail. The parasite lysates (60 µg protein per well) were resolved on 10% polyacrylamide gel under reducing conditions and transferred to Immobilon-P PVDF membrane (Millipore, Burlington MA). The membranes were blocked with 5% non-fat dry milk in 50 mM Tris pH 7.0, 150 mM NaCl (TBS) for 1 h, washed thrice with TBS -0.05% Tween 20 (TBST), and then incubated for 2 h with affinitypurified anti-TryS (1:200-dilution in TBST) or anti-GAPDH (kindly provided by Dr. C. Labriola, 1:1500 dilution) antisera. Membranes were washed with TBST and TBS, and incubated for 1 h with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Sigma-Aldrich, St. Louis, MO, 1:5000 dilution). The signal was developed and visualized by using an enhanced chemiluminescent detection reagent and hyperfilms (GE Healthcare Life Sciences, Pittsburgh, MA).
Indirect immunofluorescence assay
Epimastigotes were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS), spotted on to poly-L-lysine-treated glass slides, and permeabilized with 0.1% Triton-X 100 in PBS. Slides were washed with PBS, and incubated at room temperature for 2 h with anti-TryS antisera (1:200 dilutions in TBST). After washing with PBS thrice, slides were incubated for 1 h with Alexa fluor 488-conjugated goat anti-rabbit secondary antibody (Thermo Fisher Scientific, 1:2000 dilution) and DNA was stained with DAPI. Slides were mounted in 70% glycerol, and examined with an Axio Imager 2 fluorescence microscope (Zeiss, San Diego, CA).
Trypanothione synthetase activity
The TryS activity was determined by using the malachite green reagent that measures the amount of inorganic phosphate released from ATP during catalysis [16] . Briefly, 50-µl reaction buffer (50 mM HEPES pH 8.0, 5 mM MgCl 2 , 1 mM DTT) containing 0.5 mM GSH, 10 mM spermidine, and 1.5 mM ATP substrates was added to 96-well plates. The reagent was freshly prepared by mixing 0.5 mM aqueous solution of malachite green (M6880, Sigma), 0.034 M ammonium molybdate in 4 M HCl, and 2% Tween 20 (3.0: 1.0: 0.6, v/v/v). Parasite homogenates were prepared by using 1.5-5 × 10 7 total cells. The reaction was initiated by adding epimastigote or trypomasatigote homogenates to the wells, and after 15 min incubation at 37°C, reaction was stopped with 200 µl of malachite green reagent. The colorimetric signal was allowed to develop for 30 min, and the change in absorbance was recorded at 650 nm on a Thermo Electron Multiskan Ascent Microplate Reader (Woonsocket, RI). Total proteins were measured by Bradford colorimetric assay (Bio-Rad). All reactions were tested in triplicate and the enzymatic activity was expressed as mU per mg protein. One unit (U) of activity is defined as the amount of enzyme that catalyzes the hydrolysis of 1 μmol of ATP per minute under the conditions specified in each case.
Trypanothione (T(SH) 2 ) and glutathione (GSH) level
Epimastigotes and trypomastigotes (pTREX-and pTREX.TryStransfected) were resuspended in 4% (w/v) trichloroacetic acid (1 ×10 7 per 50 µl) and incubated at 4°C for 10 min. The lysates were centrifuged at 21,000 ×g for 30 min at 4°C, and supernatants were then lyophilized, and resuspended in 30 µl of Milli-Q water to start enzymatic T(SH) 2 determination. Samples (5 µl) were mixed in a 1:10 ratio with reaction buffer (400 µM NADPH, 5 nM recombinant trypanothione reductase, 100 mM Tris-HCl pH 7.5, 2 mM EDTA, 1 mM DTNB). T(SH) 2 -dependent DTNB reduction was measured in kinetic mode at 405 nm. GSH content was determined by a kinetic method, as described previously [17] .
Growth curve, doubling time and trypanocidal effect of TryS small molecule inhibitors
For growth curves, non-clonal and clonal populations of pTREX-and pTREX.TryS-transfected epimastigotes were synchronized by incubating them in LIT medium without FBS for 48 h. Epimastigotes were seeded in 24-well plates (5 × 10 5 parasites/well in 1 ml complete LIT medium), and parasite number was quantified daily for 12 days by using a Neubauer chamber and light microscope equipped with 40X per sample) were incubated in 1 ml PBS with 5 µM CellTrace CFSE (cat# C34554, Thermo Fisher Scientific) for 20 min, washed thrice, resuspended in 1 ml complete LIT media, and incubated again at 28°C for 3 days. Then, epimastigotes were centrifuged at 3000 RPM for 5 min, and incubated with Fixable Viability Dye eFluor 780 (1:1000 dilution in PBS, Invitrogen) at 4°C for 30 min. Thereafter, parasites were washed with PBS, and fixed with 4% formaldehyde for 20 min. Samples were visualized on a LSRII Fortessa Cell Analyzer, acquiring 100,000 events in a live cell gate, and further analysis was performed by using the FlowJo software (version 7.6.5, Tree-Star, San Carlo, CA). The TryS chemical inhibitors, KuOrb39 and KuOrb54 (S1 Figure) , were synthesized as described by Orban et al. [10] and are referred as 3d and 3 h. Synchronized, clonal parasite cultures (pTREX-and pTREX.TryS transfectants) were seeded in 96-well flat-bottom cell culture plates, and KuOrb39 or KuOrb54 (0, 5, 10, or 30 µM) added. Epimastigotes (1 × 10 4 /well/100 µl) were incubated at 28°C for 24 h and trypomastigotes (2.5 × 10 5 /well/100 µl) were incubated at 37°C / 5% CO 2 for 6 h. The growth rate of epimastigotes and survival of trypomastigotes was monitored by quantifying the motile parasites by light microscopy.
Resistance to reactive oxygen species (ROS) and anti-parasitic drugs
For this, wild type (WT), pTREX-and pTREX.TryS transfectants were seeded in 96-well flat bottom cell culture plates as above. Parasites were incubated in triplicate with H 2 O 2 (50-1000 µM), cadmium acetate (1-500 µM), nifurtimox (NFX, 1-400 µM), or benznidazole (BZ, 5-500 μM). In some experiments, parasites were co-incubated with 10-30 µM KuOrb54 or KuOrb39 to examine the effect of TryS inhibition on parasite resistance to H 2 O 2 and anti-parasitic drugs. In all experiments, epimastigotes (1 ×10 4 /well/100 µl complete LIT medium) were incubated at 28°C for 24 h and trypomastigotes (2.5 × 10 5 /well/100 µl RPMI containing 10% FBS) were incubated at 37°C / 5% CO 2 for 6 h, and viable (motile) parasites were counted by light microscopy.
Data analysis
All data were analyzed by using GraphPad Prism 5 statistical package (La Jolla, CA). Data were acquired in at least two independent experiments performed on different days (triplicate observations per experiment), and expressed as mean value ± SEM. Data were analyzed by using a Student t-test and One-way analysis of variance (ANOVA), and p values < 0.05 were considered significant. The drug activities were calculated by sigmoidal regression analysis (dose-response -inhibition model), and expressed as the concentration needed to inhibit epimastigote growth by 50% or to obtain a 50% mortality of non-replicative trypomastigotes (IC 50 ). IC 50 values are plotted as mean with a 95% confidence interval (95% CI).
Results
Transfection, overexpression and activity of TryS in T. cruzi
As a first step towards the study of TryS associated functions in the context of T. cruzi biology, we generated parasites that constitutively overexpress this enzyme. The insertion of the TryS-encoding sequence in the pTREX vector was confirmed by restriction analysis and sequencing of the TryS open reading frame. T. cruzi SylvioX10 strain belonging to TcI DTU was transfected with pTREX.TryS and control (empty pTREX) plasmids and transfectants were selected with G418. We confirmed the insertion of pTREX.TryS in the parasite's genome by A.C. Mesías et al.
Free Radical Biology and Medicine 130 (2019) [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] PCR amplification of the 320 bp fragment encoding the neomycin gene selection marker with Neo-F and Neo-R oligonucleotides, and a 900 bp DNA fragment encompassing sequences of pTREX vector and the 18 S ribosomal locus of the parasite genome by using the T7-F and RIB-R oligonucleotides (Fig. 1A) . The PCR amplification of these fragments in the transgenic but not in the WT parasites demonstrated that the pTREX ( ± TryS) was stably integrated into the ribosomal locus of T. cruzi (Fig. 1B&C) . The transfectants were cloned and all studies from this point onward were conducted in clonal populations of the transgenic cell lines. Next, we evaluated the expression and activity of TryS in the transfectants. Western blotting showed that expression of TryS (74.5 kDa) was increased by > 4-fold and > 2.5-fold in epimastigote and trypomastigote stages, respectively, of T. cruzi clones transfected with pTREX.TryS (referred as TryS hi ) when compared to the content in control transfectants (referred as pTREX) (Fig. 2A&B) (Fig. 3C ). In contrast, GSH contents in TryS hi trypomastigotes were~24% lower than that estimated in pTREX parasites, indicating its higher consumption for T(SH) 2 synthesis. Together, the results presented in Fig. 2 and Fig. 3 suggest that epimastigote and trypomastigote stages of T. cruzi stably transfected with pTREX.TryS overexpress a functionally active form of TryS.
Role of TryS in replication, differentiation and survival of T. cruzi
In T. brucei, the T(SH) 2 -system provides reducing power to sustain ribonucleotide reductase activity [18] , the enzyme responsible for deoxyribonucleotide synthesis, which are the building blocks of DNA. Thus, with the aim to analyze the effects of TryS on T. cruzi proliferation, we plotted growth curves of synchronized clonal cultures of TryS hi and control epimastigote form in complete LIT medium. The TryS hi epimastigotes exhibited a significant increase in replication than observed for the pTREX-transfected controls (doubling time: 1.77 and 2.05 days, respectively, Fig. 4A&B ), and this difference became particularly evident in the late-log phase of the growth curve. The uncloned TryS hi epimastigotes also exhibited a significantly higher rate of replication than the pTREX control epimastigotes (doubling time: 1.58 and 1.83 days, respectively, S2 Figure) at five days after seeding. Parasite proliferation was also assessed by a flow cytometry approach relying on the fluorescence loss of CFSE label after cell division. Three days after CFSE pulse labeling, 93% and 78% of the TryS hi and pTREX epimastigotes exhibited cell division, respectively (Fig. 4C) . In both groups,~99% epimastigotes were live-stained and viable (Fig. 4D) . Metacyclogenesis, i.e., differentiation of epimastigotes to metacyclic, infective trypomastigote form in the insect gut, involves the upregulation of antioxidant defense genes, such as TryS [19, 20] . We, therefore, evaluated if the TryS overexpression confers differentiation advantage to the epimastigotes. For this, TryS hi and pTREX epimastigotes were incubated in presence of triatomine gut homogenate, resembling the natural differentiation process, and the number of parasites exhibiting differentiated morphologies were recorded for 10 days. The TryS hi epimastigotes displayed a higher differentiation capacity upon stimulus as they achieved a 53% of differentiated forms out of the total population, whereas only 15% of the pTREX-transfected epimastigotes achieved metacyclic differentiation during 10 days (S3 Figure) . Further evidence of the role of TryS in replication and survival of epimastigote and infective trypomastigte forms, respectively, was obtained by incubating the transgenic clones with paullone-derived TryS- 3 . Recombinant TryS is produced as an active enzyme in epimastigote and trypomastigote forms of T. cruzi. Clonal epimastigote and trypomastigote forms of pTREX-and pTREX.TryS-transfectants were expanded as described in Materials and methods. Bar graphs present the (A) specific enzymatic activity (SEA) of TryS, (B) total trypanothione (T(SH) 2 ) content by an enzymatic recycling method, and (C) content of total GSH. The data in bar graphs are representative of ≥ 2 independent experiments (three determinations per sample per experiment) and plotted as mean value ± SEM (* and *** correspond to p < 0.05 and p < 0.001, respectively, ns stands for non-significant).
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specific inhibitors [10] . The TryS inhibitors affected the proliferation of TryS hi and control epimastigotes in a dose-dependent manner, though KuOrb39 was more effective than KuOrb54 in impairing epimastigote growth (Fig. 5A ). The growth of TryS hi and pTREX-transfected epimastigotes was decreased in presence of 30 µM KuOrb39 by 28% and 54%, respectively (p < 0.05). Likewise, TryS inhibitors affected the survival of infective, non-replicative trypomastigote forms of TryS hi and pTREX parasites in a dose-dependent manner and in this case, KuOrb54 was found to be more effective. For instance, exposure to 10 µM and 30 µM KuOrb54 resulted in a relative cell death of 25% and 52%, respectively, for TryS hi trypomastigotes, and of 50% and 75%, respectively, for wild type trypomastigotes (Fig. 5B) . Together, the results presented in Fig. 4 , cruzi.
TryS increases tolerance to oxidative stress in T. cruzi life cycle
Because T(SH) 2 can scavenge ROS or neutralize them via the T(SH) 2 -dependent antioxidant machinery of the parasite, we next examined the effect of TryS overexpression on T. cruzi's ability to survive under oxidative stress conditions. H 2 O 2 is known to be a ubiquitous reactive oxygen molecule produced by the insect as well as the mammalian host immune system [21] [22] [23] higher capacity to resist oxidative stress even in presence of KuOrb54 (Fig. 6F) .
It is known that metals may lead to an increase in ROS level and exert toxicity against T. cruzi [24] . We, therefore, investigated the effects of cadmium as an alternative oxidative stressor. The TryS hi epimastigotes exhibited a > 6-fold increase in Cd 2+ tolerance when compared to pTREX with IC 50 values of 31.4 µM and 5.1 µM, respectively (S4 Figure) . In summary, the results presented in Fig. 6 and S4 Figure suggest that: a) despite the low endogenous expression, TryS contributes to H 2 O 2 management in epimastigote form; b) TryS and other antioxidant enzymes are up-regulated in trypomastigote (vs. epimastigote) form that also appears to be more sensitive to oxidants; and c) TryS provides protection from oxidative stress in both epimastigote and trypomastigote forms of T. cruzi. Further, d) TryS displays a pivotal role in heavy metal detoxification via T(SH) 2 in T. cruzi. We surmise that up-regulation of TryS can potentially increase parasites' tolerance to oxidative stress in the vector as well as in the mammalian host.
TryS increases T. cruzi resistance to anti-parasite drug therapies
Nifurtimox (NFX) and benznidazole (BZ) are drugs of choice for the treatment of T. cruzi infection. NFX is a nitrofurane derivative, and it is believed to exert its biological activity through formation of a highly reactive and cytotoxic unsaturated open-chain nitrile [25] and, secondly, through thiol depletion [26] . To analyze the effect of TryS overexpression on parasite resistance to NFX, we incubated the pTREX and TryS hi parasites with 1-400 µM NFX, and determined the inhibition Independently of the genetic background, co-incubation with KuOrb54 significantly decreased trypomastigote resistance to NFX. Nonetheless, the effect of the TryS inhibitor was significantly less marked for TryS hi than for pTREX trypomastigotes. This was evidenced by finding of 50%, 59% and 69% cell death of pTREX trypomastigotes; and 27%, 34%, and 55% cell death of TryS hi trypomastigotes in the presence of 2.5 µM NFX only, NFX plus 10 µM, and 30 µM KuOrb54, respectively (Fig. 7E , all p < 0.05). It has been already demonstrated that benznidazole, a nitroimidazole, has a pleiotropic effect by depleting low molecular mass thiols through the formation of adducts and thereby enhancing oxidative stress [27] . The TryS hi epimastigotes showed > 4. (Fig. 8C&D , p < 0.0001). Furthermore, co-incubation with KuOrb54 significantly enhanced the toxicity of BZ against trypomastigote form independently of the genetic background. This was evidenced by finding of 50%, 64%, and 86% cell death of pTREX trypomastigotes; and 31%, 48% and 74% death of TryS hi trypomastigotes in the presence of 60 µM BZ only, BZ with 10 µM and 30 µM KuOrb54, respectively (Fig. 8E , all p < 0.05). Altogether, the results presented in Fig. 7 and Fig. 8 suggest that TryS confers NFX and BZ resistance to T. cruzi epimastigote and trypomastigote stages and that the paullone inhibitors offer a potential adjuvant therapy for enhancing nitroheterocyclic drug efficacy against T. cruzi.
Discussion
Herein, we describe the generation of recombinant T. cruzi with genomic insertion of an extra copy of the TryS gene. The aim of this approach was to elucidate the role of TryS enzyme in the context of T. cruzi biology. The TryS hi parasites, as compared to controls, exhibited increased levels of TryS protein in all stages of parasite development analyzed (Figs. 1-3) . The increased expression and activity of TryS was particularly evident in infective form when recombinant TryS led to increased T(SH) 2 synthesis from spermidine and GSH substrates. The overexpression of TryS enhanced the replication and survival of T. cruzi under physiological conditions as well as in the presence of oxidative and heavy metal stress (Figs. 4-6 and S4 Figure) . Further, overexpression of TryS conferred an advantage to the parasite to develop resistance to currently used anti-trypanosomal drugs and TryS small molecule inhibitors were efficacious in improving the efficacy of NFX and BZ against T. cruzi (Figs. 7 and 8) . The important role of TryS in parasite proliferation, infectivity and resistance against oxidative stress have previously been shown in T. brucei [18, 28] and L. infantum [29] that are related pathogenic trypanosomatids. To the best of our knowledge, this is the first study in which we have employed the genetic overexpression and small molecule inhibitors to demonstrate the biological significance of TryS in T. cruzi development, survival and resistance to oxidative stress and anti-parasite therapies. Our data allow us to propose that TryS small molecule inhibitors offer adjuvant therapy for lowering the efficacious dose of anti-parasite drugs in killing T. cruzi. The TryS enzyme produces T(SH) 2 and the latter is maintained in its reduced state by the NADPH-dependent flavoenzyme trypanothione reductase (TR) [7] . T(SH) 2 (reduced form) transfers electrons to the multipurpose thiol/disulfide oxidoreductase tryparedoxin (TXN). TXN plays a central role as biological catalyst, reducing a large diversity of molecular targets such as different types of peroxidases and ribonucleotide reductase [30] . Metabolic flux studies performed in T. cruzi highlighted that TryS/T(SH) 2 , γ-glutamylcysteine synthetase, the first enzyme of the GSH biosynthetic pathway, and TXN are the rate-limiting steps in the antioxidant network of the parasite [31] . In the T. cruzi epimastigote form that replicates and undergoes metacyclogenesis in insects, trypanothione antioxidant network was not very active. This was evidenced by the finding of low expression of TryS (Figs. 2 and 3 ) and other proteins of the antioxidant network in epimastigote form of T. cruzi [20, 32, 33] . Further, the GSH level in epimastigotes was > 2.5-fold higher than that observed in the infective stage (Fig. 3C) . Overexpression of TryS in epimastigotes was clearly insufficient to cause an increase in the T(SH) 2 content. These findings suggest that either the attained level of enzyme was yet the rate limiting step or that additional component(s) of the system (i.e. polyamine uptake) exert a higher metabolic control of the pathway. Regardless of the reasons for this metabolic output and the observed significance of GSH being the predominant low molecular weight thiol in epimastigotes (TryS hi or pTREX), our results indicate that TryS/T(SH) 2 supported growth, survival, and higher replication rate in TryS hi (vs. control) epimastigotes, a phenotype that was abolished upon selective inhibition of the enzyme (Figs. 4-6 ). Such advantageous outcomes may be associated to the fact that the T(SH) 2 -system supported the synthesis of DNA precursors [18] and the replication of the parasite mitochondrial DNA [34, 35] . Interestingly, the axenic epimastigotes displayed a marked increase in their proliferation rate during the late phase of the growth curve, when the culture milieu undergoes an important shift in the ratio of nutrients to metabolic products. Although with a lower efficiency than that occurring in the insect gut, this metabolic change triggers the differentiation of axenic epimastigotes into the highly infective and non-replicative metacyclic trypomastigotes [36, 37] . It is, thus, tempting to speculate that up-regulation of TryS under in vivo conditions may be beneficial to achieve a larger amount of epimastigotes that may undergo metacyclogenesis and establish the infective inoculum. Indeed differentiation process seems to be enhanced in TryS-overexpressing parasites (S3 Figure) when compared to the wild type clone. One possible explanation could be related to the higher content of antioxidant defenses that could be somehow monitored by the parasite as a metacyclogenesis driving force. Trypomastigotes are released from host cells and swim in interstitial fluid and bloodstream until they invade a new cell, such as macrophages. Both the extracellular medium and the invasion of activated macrophages represent an oxidative challenge for trypomastigotes. This may explain the need for a higher content of TryS/T(SH) 2 in this parasite stage. In agreement with this proposal and the almost absolute T(SH) 2 -dependency of the hydroperoxide metabolism of the parasite [38] [39] [40] , overexpression of TryS in both epimastigotes and trypomastigotes conferred protection against H 2 O 2 , a physiological oxidant produced by macrophages as part of the host immune response. The slight, but significant (p < 0.001, Fig. 6D ), difference observed between TryS hi and pTREX trypomastigotes suggests that reactions downstream to T(SH) 2 synthesis may limit the capacity of the system to neutralize or repair the damage caused by H 2 O 2 . In this regard, it is important to recall that the reaction between T(SH) 2 and TXN has been pointed to be the rate limiting step in the hydroperoxide metabolism of trypanosomatids [31, 41] . Paullones are a group of 7,12-dihydroindolo [3,2-d] [1]benzazepin-6(5 H)-ones that were initially described for their inhibitory activity against mammalian protein kinases, among other effects. Orban et al. developed novel N5 aryl-substituted derivatives of 3-chlorokenpaullone that displayed significant inhibitory activity against the recombinant TcTryS protein [10] . From this group of compounds, the on-target effect of KuOrb39 (referred as 3d in [10] ) and KuOrb54 (referred as 3 h in [10] ) was tested for the first time in T. cruzi in this study. Both compounds exerted a remarkable cytotoxic effect against both life stages of the parasite that were subject of our study. Specifically, IC 50 concentration of KuOrb54 (~10 μM) against T. cruzi parasite was similar to the levels needed to observe 50% inhibition of the recombinant enzyme [10] . The apparent higher sensitivity of trypomastigotes to the cytotoxic action of the paullones is likely explained by the fact that this stage is not replicative. In almost all assays, except for that conducted against epimastigotes at 30 μM compounds, the 4-hydroxy phenyl derivative KuOrb54 exhibited a higher cytotoxicity than the 3-chloro phenyl analogue KuOrb39. The observed plateau in anti-epimastigote activity of KuOrb54 when added at 30 μM may likely be due to an impaired uptake and/or bioavailability of this molecule. Another important finding is that KuOrb54 displayed potent anti-trypanosomal activity against a clinically relevant form of the parasite (trypomastigotes) at concentrations below (50% and 75% cell death at 10 μM and 30 μM, respectively) to that observed for the drug BZ (IC 50 = 69 μM). Conversely, KuOrb54 was comparatively less active than the potent drug NFX (IC 50 = 2 μM).
As commented previously, the mechanism of action of both antiprotozoal drugs leads to depletion of low molecular weight thiols [26, 27, 42] . The involvement of trypanothione metabolism in neutralization of nitro-drugs has been demonstrated for different trypanosome species. In T. brucei, RNAi-mediated downregulation of TryS sensitized the parasite against the action of NFX [43] . In T. cruzi, treatment with buthionine sulfoximine, an inhibitor of γ-glutamylcysteine synthetase, enhanced the anti-trypanosomal activity of NFX and/ or BZ in vitro and in vivo (unpublished observations). Here, we provide conclusive evidence for the direct implication of TryS/T(SH) 2 in the management of BZ-and NFX-induced stress in T. cruzi. The role of TryS was particularly noticeable in NFX detoxification, as the IC 50 value of NFX was estimated to be~7.5-fold higher for TryS hi parasites than that observed for pTREX trypomastigotes (Fig. 7C) . Importantly, chemical inhibition of TryS increased parasite sensitivity towards NFX and BZ (Figs. 7E and 8E) , as noted by IC 50 values for these drugs that were > 2-fold lower than those obtained in cells not exposed to paullones. Overall, these results suggest that TryS is a resistance gene for current anti-chagasic drugs, and lead us to speculate that its endogenous up-regulation -observed in some virulent parasite strains [33] -is, at least in part, associated to cases of drug failure.
Summary
By employing reverse genetics and chemical inhibition approaches, we analyzed the importance of trypanothione synthetase in T. cruzi biology. TryS proved relevant for the proliferation of the insect stage (epimastigote) of the parasite under starvation conditions, which may favor metacyclogenesis to infective trypomastigotes form. The higher expression of TryS conferred to the parasite an advantage to deal with the oxidative stress produced by different sources (e.g. H 2 O 2 and cadmium), in the replicative epimastigote as well as in the infective trypomastigotes forms of the parasite. Furthermore, T. cruzi overexpressing TryS tolerated higher dosages of anti-protozoal drugs, benznidazole and nifurtimox, suggesting that the protein may contribute to drug failure cases. Specific TryS inhibitors proved beneficial in increasing parasite's sensitivity to anti-parasitic drugs and should be considered in the design of new treatment strategies.
